Phase 2 Prostate Cancer Trial, Recruiting NCT07220720 Sponsor: University of Florida Condition: Prostate Cancer
Back to Prostate Cancer

Phase 2 Prostate Cancer Trial, Recruiting

NCT07220720
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing to sign a consent form and are able to follow all the steps required by the study.
  • You are male and at least 18 years old.
  • You have never had a prostate biopsy before.
  • You had a special type of MRI scan of your pelvis (called an mpMRI) within the last 90 days to check for possible prostate cancer.
  • You are already scheduled to have a targeted biopsy procedure that uses MRI and ultrasound images together.
  • Your MRI scan showed certain findings rated as PIRADS 2 or PIRADS 3 (a scoring system used by radiologists to describe areas of possible concern in the prostate — confirm with trial site if unsure what your score is).

Who may not be able to join:

  • You have already been diagnosed with prostate cancer.
  • You have a medical condition or situation that, in the doctor's judgment, could affect the study results or make it hard for you to complete the study (confirm with trial site).
  • You have taken part in another interventional clinical trial in the last 30 days.
  • You have a known allergy or sensitivity to the ingredients in a specific imaging drug called flotufolastat F 18, used in a PET-CT scan (confirm with trial site if you are unsure about your allergies).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 904-244-7340

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
4 November 2025
Est. completion
15 July 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in positive predictive value (PPV); Change in negative predictive value (NPV); Improvement in Accuracy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov